Literature DB >> 24728736

Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review.

O Bargiacchi1, A Rossati, P Car, D Brustia, R Brondolo, F Rosa, P L Garavelli, F G De Rosa.   

Abstract

We report three cases of external ventricular derivation infections caused by multidrug-resistant Gram-negative rods and treated successfully with intraventricular colistin. The intrathecal or intraventricular use of colistin have been reported in more than 100 cases without any consensus on dosage, duration and type (monotherapy or combination therapy) of treatment. Based on our comprehensive review of the relevant literature relating to both clinical and pharmacokinetic data, we conclude that the intrathecal/intraventricular administration of colistin is a safe and effective option to treat central nervous system infections caused by multidrug-resistant Gram-negative bacteria.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24728736     DOI： 10.1007/s15010-014-0618-0

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  60 in total

1.  Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.

Authors:  P Fernandez-Viladrich; X Corbella; L Corral; F Tubau; A Mateu
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E.

Authors:  Mony Benifla; Gideon Zucker; Avi Cohen; Michael Alkan
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

3.  Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review.

Authors:  John Ng; Iain B Gosbell; John A Kelly; Michael J Boyle; John K Ferguson
Journal:  J Antimicrob Chemother       Date:  2006-08-17       Impact factor: 5.790

4.  Acinetobacter species meningitis in children: a case series from Karachi, Pakistan.

Authors:  Ali Faisal Saleem; Muhammad Shafaat Shah; Abdul Sattar Shaikh; Fatima Mir; Anita K M Zaidi
Journal:  J Infect Dev Ctries       Date:  2011-11-15       Impact factor: 0.968

5.  Intraventricular antimicrobial therapy in postneurosurgical Gram-negative bacillary meningitis or ventriculitis: a hospital-based retrospective study.

Authors:  Jui-Hsing Wang; Po-Chang Lin; Chia-Hui Chou; Cheng-Mao Ho; Kuo-Hsi Lin; Chia-Ta Tsai; Jen-Hsien Wang; Chih-Yu Chi; Mao-Wang Ho
Journal:  J Microbiol Immunol Infect       Date:  2012-11-30       Impact factor: 4.399

6.  Multidrug-resistant Acinetobacter baumannii ventriculitis: successful treatment with intraventricular colistin.

Authors:  B López-Alvarez; R Martín-Láez; M C Fariñas; B Paternina-Vidal; J D García-Palomo; A Vázquez-Barquero
Journal:  Acta Neurochir (Wien)       Date:  2009-05-08       Impact factor: 2.216

7.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

Review 8.  Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review.

Authors:  T Khawcharoenporn; A Apisarnthanarak; L M Mundy
Journal:  Clin Microbiol Infect       Date:  2009-08-17       Impact factor: 8.067

9.  Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.

Authors:  Wang Liang; Xiao-Fang Liu; Jun Huang; De-Mei Zhu; Jian Li; Jing Zhang
Journal:  BMC Infect Dis       Date:  2011-04-27       Impact factor: 3.090

10.  Intrathecal colistin for treatment of Pseudomonas aeruginosa ventriculitis: report of a case with successful outcome.

Authors:  Rezzan Yagmur; Figen Esen
Journal:  Crit Care       Date:  2006       Impact factor: 9.097
View more
  8 in total

1.  Local complications of adjunct intrathecal antibiotics for nosocomial meningitis associated with gram-negative pathogens: a meta-analysis.

Authors:  Alexandros G Brotis; Isaac Churis; Marios Karvouniaris
Journal:  Neurosurg Rev       Date:  2019-12-24       Impact factor: 3.042

2.  Frequent use of colistin-based drug treatment to eliminate extended-spectrum beta-lactamase-producing Escherichia coli in backyard chicken farms in Thai Binh Province, Vietnam.

Authors:  Tatsuya Nakayama; Michio Jinnai; Ryuji Kawahara; Khong Thi Diep; Nguyen Nam Thang; Tran Thi Hoa; Le Kieu Hanh; Pham Ngoc Khai; Yoshinori Sumimura; Yoshimasa Yamamoto
Journal:  Trop Anim Health Prod       Date:  2016-09-23       Impact factor: 1.559

3.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251

4.  Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis.

Authors:  Mariadelfina Molinaro; Paola Morelli; Manuela De Gregori; Simona De Gregori; Ilaria Giardini; Federica Tordato; Vincenzina Monzillo; Daria Pocaterra; Erminia Casari
Journal:  Infect Drug Resist       Date:  2018-09-03       Impact factor: 4.003

5.  Colistin for Treatment of Multidrug Resistant Central Nervous System Infection: A Triple Route Therapy!

Authors:  Ratnesh Kumar Shukla; Indu Kapoor; Charu Mahajan; Hemanshu Prabhakar
Journal:  Indian J Crit Care Med       Date:  2019-06

6.  Intrathecal Injection of Tigecycline and Polymyxin B in the Treatment of Extensively Drug-Resistant Intracranial Acinetobacter baumannii Infection: A Case Report and Review of the Literature.

Authors:  Ziyu Li; Yuling An; Lijuan Li; Huimin Yi
Journal:  Infect Drug Resist       Date:  2022-03-31       Impact factor: 4.003

7.  Colistin and tigecycline for management of external ventricular device-related ventriculitis due to multidrug-resistant Acinetobacter baumannii.

Authors:  Gentle Sunder Shrestha; Sushil Tamang; Hem Raj Paneru; Pramesh Sunder Shrestha; Niraj Keyal; Subhash Prasad Acharya; Moda Nath Marhatta; Sushil Shilpakar
Journal:  J Neurosci Rural Pract       Date:  2016 Jul-Sep

Review 8.  Intrathecal/Intraventricular Colistin for Antibiotic-Resistant Bacterial CNS Infections in Pediatric Population: A Systematic Review.

Authors:  Ibrahim Alnaami; Zubaidah Alahmari
Journal:  Trop Med Infect Dis       Date:  2022-03-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.